Document Page: First | Prev | Next | All | Image | This Release | Search
File: 970101_sep96_decls32_0001.txt
Subject: RECOMMENDATION CONCERNING THE USE OF CIPROFLOXACIN
Unit: OTSG
Parent Organization: HSC
Box ID: BX003201
Folder Title: RECOMMENTATION CONCERNING THE USE OF CIPROFLOXACIN
Document Number: 1001
Folder Seq #: 22
6@c @P
UNCLASSIFIED
DEPARTMENT OF DEFENSE
ARMED FORCES EPIDEMIOLOGICAL BOARD
5109 LEESBURG PIKE
FALLS CHURCH, VA22041-3258 4
.
AFEB (15-1a) 17 December 1990
MEMORANDUM FOR THE ASSISTANT SECRETARY OF DEFENSE (HEALTH AFFAIRS)
THE SURGEON GENERAL, DEPARTMENT OF THE ARMY
THE SURGEON GENERAL, DEPARTMENT OF THE NAVY
THE SURGEON GENERAL, DEPARTMENT OF THE AIR FORCE
SUBJECT: [U] Recommendation Concerning the Use of Ciprofloxacin
1. On 14 December 1990 appropriate members of the Disease Control
Subcommittee of the Armed Forces Epidemiological Board were
requested by the Surgeon General, Department of the Army (SGSP-
PSP), to consider the use of Ciprofloxacin as an adjunct in
countering the threat of inhalation anthrax. The basic request is
provided at enclosure (1). Dr. Theodore E. Woodward, Dr. Abram S.
Benenson, and Dr. Scott B. Halstead met with appropriate service
representatives on 17 December 1990 to review existing information
and the proposed application of Ciprofloxacin.
2. Based on the data presented and subsequent discussions the
Board:
a. Concurs with the use of Ciprofloxacin as an adjunct
countermeasure against inhalation anthrax. The doctrine for use is
understood to be as follows:
(1) All service merabers will be issued a blister pack of
ten Ciprofloxacin tablets (500mg) with instructions to take one
tablet every 12 hours. The decision to begin taking the antibiotic
he tactical commander.
(2) If potential exposure to anthrax is confirmed the
service member must receive at least one anthrax vaccine booster
immunization and be provided with sufficient Ciprofloxacin to be
taken for 30 days. Should suspicious clinical symptoms occur the
service member will be treated with oral ciprofloxacin (1000 mg
loading dose followed by 750 mg twice daily), intravenous
doxycycline (200 mg loading dose followed by 100 mg two times
daily), or other appropriate antibiotics based on bacterial
sensitivity testing.
b. Strongly recommends that specimens be cultured, identified
and tested for antibiotic sensitivity utilizing resources available
in-theatre. It is considered essential that this information be
available without delay to determine preventive measures and permit
CLASSIFIED BY: MULTIPLE SOURCES
DECLASSIFY BY: OASD
OA UNCLASSIFIED
DECLASSIFIED
ON: 12 DEC 96
BY: SEC ARMY (DAMH) UNDER SEC 3.4 EO 12958
Document Page: First | Prev | Next | All | Image | This Release | Search
Document 2 f:/Week-36/BX003201/RECOMMENTATION CONCERNING THE USE OF CIPROFLOXACIN/recommendation concerning the use of ciprofloxac:12249609312933
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003201
Unit = OTSG
Parent Organization = HSC
Folder Title = RECOMMENTATION CONCERNING THE USE OF CIPROFLOXACIN
Folder Seq # = 22
Subject = RECOMMENDATION CONCERNING THE USE OF CIPROFLOXAC
Document Seq # = 1001
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 24-DEC-1996